Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Leukemia, Myeloid, Acute | 27 | 2024 | 3599 | 4.540 |
Why?
|
Sulfonamides | 10 | 2024 | 1972 | 1.710 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 4 | 2024 | 1546 | 1.560 |
Why?
|
Trisomy | 2 | 2024 | 260 | 1.540 |
Why?
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2024 | 381 | 1.350 |
Why?
|
Asparaginase | 2 | 2024 | 240 | 1.060 |
Why?
|
Antibodies, Bispecific | 2 | 2023 | 191 | 0.890 |
Why?
|
Myelodysplastic Syndromes | 5 | 2024 | 1392 | 0.820 |
Why?
|
Staurosporine | 2 | 2021 | 242 | 0.790 |
Why?
|
Dioxygenases | 1 | 2024 | 332 | 0.790 |
Why?
|
Lymphoma, T-Cell | 1 | 2024 | 304 | 0.750 |
Why?
|
fms-Like Tyrosine Kinase 3 | 6 | 2024 | 495 | 0.730 |
Why?
|
Hypertriglyceridemia | 1 | 2023 | 293 | 0.710 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 15 | 2024 | 11709 | 0.710 |
Why?
|
Pyrazines | 2 | 2024 | 1198 | 0.690 |
Why?
|
Neutropenia | 2 | 2022 | 885 | 0.670 |
Why?
|
Depsipeptides | 1 | 2019 | 95 | 0.660 |
Why?
|
Cytarabine | 5 | 2024 | 697 | 0.640 |
Why?
|
Lymphoma, T-Cell, Peripheral | 1 | 2019 | 124 | 0.610 |
Why?
|
Lymphoma, T-Cell, Cutaneous | 1 | 2019 | 209 | 0.580 |
Why?
|
Gastritis | 1 | 2019 | 199 | 0.580 |
Why?
|
Antibiotics, Antineoplastic | 2 | 2023 | 675 | 0.560 |
Why?
|
Neoplasms, Second Primary | 1 | 2024 | 1051 | 0.520 |
Why?
|
Mutation | 10 | 2024 | 29928 | 0.470 |
Why?
|
Venous Thromboembolism | 2 | 2024 | 1847 | 0.460 |
Why?
|
Lymphoma | 1 | 2023 | 1900 | 0.450 |
Why?
|
Hematopoietic Stem Cell Transplantation | 6 | 2024 | 5648 | 0.410 |
Why?
|
Proto-Oncogene Proteins | 1 | 2024 | 4491 | 0.390 |
Why?
|
Prognosis | 11 | 2024 | 29493 | 0.370 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2021 | 1627 | 0.340 |
Why?
|
DNA Methylation | 1 | 2024 | 4374 | 0.340 |
Why?
|
Protein Kinase Inhibitors | 3 | 2022 | 5639 | 0.330 |
Why?
|
Remission Induction | 4 | 2024 | 2391 | 0.320 |
Why?
|
Aniline Compounds | 2 | 2024 | 1068 | 0.300 |
Why?
|
DNA-Binding Proteins | 2 | 2024 | 9574 | 0.290 |
Why?
|
Humans | 52 | 2024 | 757650 | 0.280 |
Why?
|
Echocardiography | 1 | 2019 | 4962 | 0.270 |
Why?
|
Risk Assessment | 3 | 2023 | 23819 | 0.260 |
Why?
|
Leukemia | 2 | 2024 | 1521 | 0.240 |
Why?
|
Salvage Therapy | 2 | 2022 | 1264 | 0.240 |
Why?
|
Recurrence | 5 | 2024 | 8426 | 0.230 |
Why?
|
Class Ib Phosphatidylinositol 3-Kinase | 1 | 2024 | 43 | 0.230 |
Why?
|
Daunorubicin | 1 | 2024 | 156 | 0.230 |
Why?
|
Kidney Transplantation | 1 | 2019 | 4214 | 0.230 |
Why?
|
Chromosome Inversion | 1 | 2024 | 120 | 0.220 |
Why?
|
Idarubicin | 1 | 2023 | 59 | 0.220 |
Why?
|
Antineoplastic Agents | 2 | 2024 | 13603 | 0.220 |
Why?
|
p21-Activated Kinases | 1 | 2024 | 128 | 0.220 |
Why?
|
Chromosomes, Human, Pair 3 | 1 | 2024 | 315 | 0.220 |
Why?
|
Isocitrate Dehydrogenase | 3 | 2024 | 928 | 0.220 |
Why?
|
Sunlight | 1 | 2024 | 337 | 0.200 |
Why?
|
Young Adult | 8 | 2024 | 58764 | 0.200 |
Why?
|
Karyotyping | 1 | 2024 | 1171 | 0.200 |
Why?
|
Review Literature as Topic | 1 | 2023 | 346 | 0.190 |
Why?
|
Disseminated Intravascular Coagulation | 1 | 2022 | 187 | 0.190 |
Why?
|
Retrospective Studies | 16 | 2024 | 79982 | 0.190 |
Why?
|
Hematologic Neoplasms | 2 | 2024 | 1890 | 0.180 |
Why?
|
Anemia, Aplastic | 1 | 2022 | 228 | 0.180 |
Why?
|
Monoclonal Gammopathy of Undetermined Significance | 1 | 2022 | 179 | 0.180 |
Why?
|
Chromosomes, Human, Pair 8 | 1 | 2021 | 452 | 0.170 |
Why?
|
Azacitidine | 1 | 2021 | 334 | 0.170 |
Why?
|
Paraproteinemias | 1 | 2022 | 246 | 0.170 |
Why?
|
Glucose-6-Phosphate | 1 | 2019 | 29 | 0.170 |
Why?
|
Adult | 16 | 2024 | 219747 | 0.170 |
Why?
|
Middle Aged | 18 | 2024 | 219219 | 0.160 |
Why?
|
Leukemia, Myeloid | 1 | 2022 | 695 | 0.160 |
Why?
|
Chromosomal Proteins, Non-Histone | 1 | 2024 | 727 | 0.160 |
Why?
|
Aged | 15 | 2024 | 167889 | 0.160 |
Why?
|
Lymphoma, Follicular | 1 | 2023 | 453 | 0.160 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 2 | 2024 | 1727 | 0.160 |
Why?
|
ras Proteins | 1 | 2024 | 1050 | 0.160 |
Why?
|
Aged, 80 and over | 9 | 2024 | 58559 | 0.160 |
Why?
|
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2020 | 223 | 0.150 |
Why?
|
Retreatment | 1 | 2019 | 596 | 0.150 |
Why?
|
Adolescent | 7 | 2024 | 87832 | 0.150 |
Why?
|
Disease-Free Survival | 3 | 2023 | 6808 | 0.150 |
Why?
|
Lymphoma, B-Cell, Marginal Zone | 1 | 2019 | 178 | 0.150 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2022 | 685 | 0.140 |
Why?
|
Antigens, CD19 | 1 | 2020 | 424 | 0.140 |
Why?
|
Male | 18 | 2024 | 358227 | 0.140 |
Why?
|
Postoperative Complications | 1 | 2019 | 15532 | 0.140 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2020 | 642 | 0.130 |
Why?
|
Combined Modality Therapy | 3 | 2024 | 8515 | 0.130 |
Why?
|
T-Lymphocytes | 2 | 2024 | 10172 | 0.130 |
Why?
|
Helicobacter pylori | 1 | 2019 | 376 | 0.130 |
Why?
|
Helicobacter Infections | 1 | 2019 | 385 | 0.130 |
Why?
|
Chromosome Aberrations | 1 | 2021 | 1764 | 0.120 |
Why?
|
Thrombocytopenia | 1 | 2022 | 1173 | 0.120 |
Why?
|
Survival Rate | 3 | 2024 | 12685 | 0.120 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 1 | 2023 | 1402 | 0.110 |
Why?
|
Pyridones | 1 | 2019 | 785 | 0.110 |
Why?
|
Disease Management | 1 | 2024 | 2495 | 0.110 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2024 | 2913 | 0.110 |
Why?
|
Methotrexate | 1 | 2020 | 1718 | 0.110 |
Why?
|
Child | 5 | 2024 | 79787 | 0.110 |
Why?
|
Dendritic Cells | 1 | 2024 | 2723 | 0.110 |
Why?
|
Incidence | 4 | 2024 | 21217 | 0.110 |
Why?
|
Nuclear Proteins | 2 | 2024 | 5786 | 0.110 |
Why?
|
Cell Cycle Proteins | 1 | 2024 | 3443 | 0.100 |
Why?
|
Abdominal Pain | 1 | 2019 | 1064 | 0.100 |
Why?
|
Bone Marrow | 1 | 2023 | 2910 | 0.100 |
Why?
|
Female | 15 | 2024 | 389985 | 0.100 |
Why?
|
Kaplan-Meier Estimate | 2 | 2020 | 6469 | 0.100 |
Why?
|
Ventricular Dysfunction, Left | 1 | 2023 | 2115 | 0.100 |
Why?
|
Overweight | 1 | 2023 | 2408 | 0.100 |
Why?
|
Antigens, Neoplasm | 1 | 2020 | 1994 | 0.100 |
Why?
|
Dyspnea | 1 | 2019 | 1344 | 0.100 |
Why?
|
Glomerular Filtration Rate | 1 | 2019 | 2152 | 0.090 |
Why?
|
Ventricular Function, Left | 2 | 2023 | 3858 | 0.090 |
Why?
|
Pulmonary Artery | 1 | 2019 | 1916 | 0.090 |
Why?
|
Israel | 2 | 2023 | 721 | 0.080 |
Why?
|
C-Reactive Protein | 1 | 2020 | 3811 | 0.080 |
Why?
|
Pyrazoles | 1 | 2019 | 1994 | 0.080 |
Why?
|
Acute Kidney Injury | 1 | 2020 | 1923 | 0.070 |
Why?
|
Cyclopentanes | 1 | 2007 | 86 | 0.070 |
Why?
|
Acute Coronary Syndrome | 1 | 2019 | 2180 | 0.070 |
Why?
|
Drug Resistance, Neoplasm | 2 | 2019 | 5254 | 0.070 |
Why?
|
Body Mass Index | 1 | 2023 | 12870 | 0.060 |
Why?
|
Cohort Studies | 4 | 2024 | 41198 | 0.060 |
Why?
|
Multiple Myeloma | 1 | 2022 | 5129 | 0.060 |
Why?
|
Chondroitin Sulfate Proteoglycans | 1 | 2024 | 141 | 0.060 |
Why?
|
Melanoma, Experimental | 1 | 2007 | 559 | 0.060 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2007 | 621 | 0.050 |
Why?
|
Positron-Emission Tomography | 1 | 2019 | 6457 | 0.050 |
Why?
|
Treatment Outcome | 4 | 2024 | 64242 | 0.050 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2021 | 5272 | 0.050 |
Why?
|
Oxidative Phosphorylation | 1 | 2024 | 495 | 0.050 |
Why?
|
Risk Factors | 3 | 2024 | 73716 | 0.050 |
Why?
|
Anthracyclines | 1 | 2023 | 282 | 0.050 |
Why?
|
Obesity | 1 | 2023 | 12869 | 0.050 |
Why?
|
Signal Transduction | 1 | 2024 | 23342 | 0.050 |
Why?
|
Follow-Up Studies | 2 | 2020 | 39018 | 0.050 |
Why?
|
Atrial Fibrillation | 1 | 2019 | 5105 | 0.040 |
Why?
|
Antibody Specificity | 1 | 2020 | 1060 | 0.040 |
Why?
|
Lung Neoplasms | 2 | 2021 | 13267 | 0.040 |
Why?
|
Clinical Trials as Topic | 2 | 2023 | 7982 | 0.040 |
Why?
|
Multicenter Studies as Topic | 1 | 2022 | 1702 | 0.040 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2024 | 1594 | 0.030 |
Why?
|
Tomography, X-Ray Computed | 1 | 2019 | 20499 | 0.030 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2024 | 3575 | 0.030 |
Why?
|
Risk Adjustment | 1 | 2019 | 599 | 0.030 |
Why?
|
Disease Susceptibility | 1 | 2022 | 1788 | 0.030 |
Why?
|
Phosphoproteins | 1 | 2024 | 2433 | 0.030 |
Why?
|
Neoplasms | 1 | 2024 | 21990 | 0.030 |
Why?
|
Neoplasm, Residual | 1 | 2020 | 1005 | 0.030 |
Why?
|
Transplantation Conditioning | 1 | 2021 | 1588 | 0.030 |
Why?
|
Anticoagulants | 2 | 2021 | 4776 | 0.030 |
Why?
|
Hematopoiesis | 1 | 2023 | 2047 | 0.030 |
Why?
|
Causality | 1 | 2019 | 1241 | 0.030 |
Why?
|
Phosphorylation | 1 | 2024 | 8298 | 0.030 |
Why?
|
Transplantation, Homologous | 1 | 2021 | 4808 | 0.030 |
Why?
|
Age Factors | 2 | 2019 | 18328 | 0.030 |
Why?
|
Enzyme Inhibitors | 1 | 2022 | 3709 | 0.020 |
Why?
|
Molecular Targeted Therapy | 1 | 2023 | 2796 | 0.020 |
Why?
|
Gastrointestinal Diseases | 1 | 2020 | 1184 | 0.020 |
Why?
|
Mitochondria | 1 | 2024 | 3584 | 0.020 |
Why?
|
Hemorrhage | 1 | 2022 | 3399 | 0.020 |
Why?
|
Cell Line | 1 | 2024 | 15594 | 0.020 |
Why?
|
Epigenesis, Genetic | 1 | 2023 | 3754 | 0.020 |
Why?
|
Cross-Sectional Studies | 2 | 2022 | 25931 | 0.020 |
Why?
|
Stroke Volume | 1 | 2023 | 5460 | 0.020 |
Why?
|
Nervous System Diseases | 1 | 2020 | 1647 | 0.020 |
Why?
|
Patient Selection | 1 | 2019 | 4235 | 0.020 |
Why?
|
Immunotherapy | 1 | 2023 | 4641 | 0.020 |
Why?
|
Longitudinal Studies | 1 | 2023 | 14478 | 0.020 |
Why?
|
Oxylipins | 1 | 2007 | 52 | 0.020 |
Why?
|
Sex Factors | 1 | 2019 | 10497 | 0.020 |
Why?
|
Acetates | 1 | 2007 | 321 | 0.020 |
Why?
|
Prevalence | 1 | 2022 | 15641 | 0.020 |
Why?
|
Comorbidity | 1 | 2019 | 10478 | 0.020 |
Why?
|
Cytokines | 1 | 2020 | 7339 | 0.020 |
Why?
|
Drug Screening Assays, Antitumor | 1 | 2007 | 714 | 0.010 |
Why?
|
Pandemics | 1 | 2023 | 8601 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2019 | 15209 | 0.010 |
Why?
|
Mice | 2 | 2024 | 81107 | 0.010 |
Why?
|
Stroke | 1 | 2019 | 9695 | 0.010 |
Why?
|
Animals | 2 | 2024 | 167777 | 0.010 |
Why?
|
Prospective Studies | 1 | 2019 | 54108 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2007 | 16891 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2007 | 22008 | 0.000 |
Why?
|